Concepedia

Edgar D. Charles

ED

35

Publications

3K

Citations

25

H-Index

1974

Active since

Affiliations

Bristol-Myers Squibb (United States)(Current)

Rockefeller University

Texas Liver Institute

Virginia Commonwealth University

Saint Louis University

Edgar D. Charles is an author at Bristol-Myers Squibb (United States) specializing in medicine, liver physiology, and immunology.

ORCID

Top concepts

Publications per year

1974–2024

35

Publications

35

Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial

Arun J. Sanyal, Edgar D. Charles, Brent A. Neuschwander‐Tetri et al. · The Lancet · 2018 · 511 citations

, , +7

Pegbelfermin (BMS‐986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study

Edgar D. Charles, Brent A. Neuschwander‐Tetri, Juan P. Frías et al. · Obesity · 2018 · 243 citations · Full text

Cell culture–produced hepatitis C virus does not infect peripheral blood mononuclear cells

Svetlana Marukian, Christopher T. Jones, Linda Andrus et al. · Hepatology · 2008 · 237 citations · Full text

Clonal B cells in patients with hepatitis C virus–associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset

Edgar D. Charles, Claudia Brunetti, Svetlana Marukian et al. · Blood · 2011 · 203 citations

Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C

David Butera, Svetlana Marukian, Amy E. Iwamaye et al. · Blood · 2005 · 176 citations · Full text

Rows per page

1–5 of 35